|
Report No. : |
306474 |
|
Report Date : |
11.02.2015 |
IDENTIFICATION DETAILS
|
Name : |
GENERA PHARMA AG |
|
|
|
|
Registered Office : |
Färberstrasse 4, 8832 Wollerau/SZ, Switzerland/CH |
|
|
|
|
Country : |
Switzerland
|
|
|
|
|
Date of Incorporation : |
1981 |
|
|
|
|
Com. Reg. No.: |
260.3.000.312-2 / 67978 |
|
|
|
|
Legal Form : |
Company limited by shares |
|
|
|
|
Line of Business : |
Manufacturing, packaging and distribution of pharmaceutical, dietary, cosmetic
and veterinary products. |
|
|
|
|
No. of Employees : |
2 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
Payment Behaviour : |
Unknown |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – December 31, 2014
|
Country Name |
Previous Rating (30.09.2014) |
Current Rating (31.12.2014) |
|
Switzerland |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
SWITZERLAND - ECONOMIC OVERVIEW
Switzerland is a peaceful, prosperous,
and modern market economy with low unemployment, a highly skilled labor force,
and a per capita GDP among the highest in the world. Switzerland's economy
benefits from a highly developed service sector, led by financial services, and
a manufacturing industry that specializes in high-technology, knowledge-based
production. Its economic and political stability, transparent legal system,
exceptional infrastructure, efficient capital markets, and low corporate tax
rates also make Switzerland one of the world's most competitive economies. The
Swiss have brought their economic practices largely into conformity with the
EU's to enhance their international competitiveness, but some trade
protectionism remains, particularly for its small agricultural sector. The fate
of the Swiss economy is tightly linked to that of its neighbors in the euro
zone, which purchases half of all Swiss exports. The global financial crisis of
2008 and resulting economic downturn in 2009 stalled export demand and put
Switzerland in a recession. The Swiss National Bank (SNB) during this period
effectively implemented a zero-interest rate policy to boost the economy as
well as prevent appreciation of the franc, and Switzerland's economy began to
recover in 2010. The sovereign debt crises currently unfolding in neighboring
euro-zone countries pose a significant risk to Switzerland's financial
stability and are driving up demand for the Swiss franc by investors seeking a
safe-haven currency. The independent SNB has upheld its zero-interest rate
policy and conducted major market interventions to prevent further appreciation
of the Swiss franc, but parliamentarians have urged it to do more to weaken the
currency. The franc's strength has made Swiss exports less competitive and
weakened the country's growth outlook; GDP growth fell below 2% per year during
2011-13. Switzerland has also come under increasing pressure from individual
neighboring countries, the EU, the US, and international institutions to reform
its banking secrecy laws. Consequently, the government agreed to conform to
OECD regulations on administrative assistance in tax matters, including tax
evasion. The government has renegotiated its double taxation agreements with
numerous countries, including the US, to incorporate the OECD standard, and is
considering the possibility of imposing taxes on bank deposits held by
foreigners. These steps will have a lasting impact on Switzerland's long
history of bank secrecy.
|
Source
: CIA |
GENERA PHARMA AG
Färberstrasse 4
8832 Wollerau/SZ
Switzerland/CH
Telephone: 044 6872868
WIN Worldbox No.:CH0000189804
VAT-No.: CHE-104.028.179
MWST
UID-No.: CHE104028179
Established: 1981
Line of Business: Pharmaceutics
Industry Division: Manufacturing
Industry-code (NACE): 2110 Manufacture of basic pharmaceutical
products
Banks: unknown
Coverage: Company
Figures: estimated
Financial year: 2014
Employees: 2
Sales: CHF 3,400,000.--
The business is the manufacturing, packaging and distribution of
pharmaceutical, dietary, cosmetic and veterinary products.
The company sells Elcarnitol sports bars and similar products.
Real Estate: The company does
not appear to own any property.
Company No: 260.3.000.312-2 /
67978
Legal form: Company limited
by shares
Registration: 23.12.2005
Legal status: active
Responsible Register: Handelsregister
des Kantons Schwyz
History: Date of Incorporation
Statutes: 01.06.1983
Date of Statutes:
22.12.2008
Date of Statutes:
28.10.2005
Date of Statutes:
24.12.2005
Entry Deleted Name
23.12.2005 GENERA
PHARMA AG
18.06.2004 23.12.2005 Genera Pharma AG
Entry Deleted Legal
domicile
23.12.2005 Wollerau,
Switzerland
18.06.2004 23.12.2005 Solothurn, Switzerland
Entry Deleted Address
21.01.2013 Färberstrasse 4, 8832 Wollerau/SZ,
Switzerland/CH
16.01.2007 21.01.2013 Wilenstrasse 4, 8832 Wollerau,
Switzerland/CH
18.09.2006 16.01.2007 Sihleggstrasse 23, 8832 Wollerau/SZ,
Switzerland/CH
23.12.2005 18.09.2006 bei élu produits naturels sa,
Sihleggstrasse 23, 8832 Wollerau/SZ, Switzerland/CH
18.06.2004 23.12.2005 Hilariweg 9, 4500 Solothurn/SO,
Switzerland/CH
Entry Deleted Capital
23.12.2005 Share
Capital CHF 50,000, paidup CHF 50,000
Entry Deleted Capital Structure
23.12.2005 500
Bearer shares of CHF 100.--
Title Name
Director Gkioultzin
Bilgkits
Citizen: Griechenland,
Switzerland
Residential address:
8832 Wollerau, Switzerland
single signature
Registered since:
18.09.2006
Title Name
Member with signing authority Ziya
Serdar Neptun
Citizen: Turkey
Residential address:
Istanbul , Turkey
single signature
Registered since:
21.12.2004
No. of Owner/-s: 1
Owner: The company is privately
owned.
Class: 100%
Type: direct
Name: Gkioultzin Bilgkits
City/Country: Wollerau,
Switzerland/CH
Interest: 100,00% voting
right, 100,00% capital interest
It is believed that the company has no investments.
Balance sheet publication:
The subject company does not publish balance sheet or turnover figures.
Control date Year No. Amount
CHF Status
22.06.2009 2009 0 Legal
actions
31.12.2008 2008 0 Legal
actions
31.12.2007 2007 0 Legal
actions
Official bankruptcy reports:
No bankruptcy publications available on the subject.
An updated legal action check is only available against proof of
interest. e.g. a copy of an enquiry letter, and order or invoice relating to
the subject company.
The company is not listed in the WorldCompliance database.
Payment experiences from pre-legal collection cases:
No payment experiences from pre-legal collection cases are available.
Payment experiences from collection cases:
No payment experiences from legal collection cases are available.
Mode of payment / Business conduct:
There are no complaints about the mode of payment and the business
conduct.
Financial Statements: The company
does not disclose any financial statements. Third parties are not permitted any
insight into the financial affairs. It is therefore difficult to make a proper
assessment of the actual situation.
Financial Situation: The
financial situation is difficult to assess.
Payment experiences: There are no
objections regarding the payment of financial obligations.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.61.96 |
|
|
1 |
Rs.94.41 |
|
Euro |
1 |
Rs.70.20 |
INFORMATION DETAILS
|
Analysis Done by
: |
DIV |
|
|
|
|
Report Prepared
by : |
TPT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to
overcome financial difficulties seems comparatively below average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major sections
of this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.